Skip to main content

Transarterielle Chemoembolisation von Lebermetastasen kolorektaler Karzinome mit abbaubaren Stärkepartikeln (Spherex®)

Eigene Beobachtungen und Literaturübersicht

Transcatheter arterial chemoembolization of colorectal liver metastases using degradable starch microspheres (Spherex®)

Own investigations and review to the literature

Der Radiologe volume 45, pages 633–643 (2005)Cite this article

Zusammenfassung

Seit Beginn der 80er Jahre ist die transarterielle Chemoembolisation (TACE) von Lebermetastasen Gegenstand zahlreicher Studien, ohne dass sich bisher ein einheitliches Therapiekonzept durchgesetzt hat.

Die vorgestellte Studie untersuchte bei 21 Patienten mit inoperablen Lebermetastasen kolorektaler Karzinome retrospektiv die Überlebenszeiten, Ansprechraten und Nebenwirkungen nach TACE, und die Ergebnisse werden den Daten der bisherigen Literatur gegenübergestellt. Insgesamt wurden 68 TACE durchgeführt. Eine Suspension aus abbaubaren Stärkepartikel (degradable starch microspheres, DSM; Spherex®) und Mitomycin C wurde über einen transfemoralen Zugang selektiv in die Leberarterien appliziert. DSM bewirkt eine temporäre arterielle Okklusion. Die Therapiekontrolle erfolgte mit kontrastmittelunterstützter Spiralcomputertomographie (CT).

Die mediane Überlebenszeit betrug 13,8 Monate. Ein Ansprechen (nach WHO-Kriterien) wurde lediglich bei 3 Patienten beobachtet, das progressfreie Intervall lag im Median bei 5,8 Monaten. Als Nebenwirkung traten ein Postembolisationssyndrom (abdominelle Schmerzen, Fieber, Übelkeit) sowie eine Erhöhung der Transaminasen bei 27–43% der Interventionen auf. Nach 4 TACE kam es zur Entstehung eines Magenulkus, nach 2 TACE zu einer Cholezystitis.

Wie in den meisten vorangegangenen Arbeiten, ungeachtet der eingesetzten Substanzen, ist auch in dieser Studie der therapeutische Effekt der TACE von Lebermetastasen kolorektaler Karzinome eher als mäßig einzustufen. Ein Überlebensvorteil gegenüber dem Spontanverlauf konnte bisher in der Literatur nicht eindeutig belegt werden, die Ansprechraten sind meistens sehr begrenzt. Komplikationen sind bei der TACE insgesamt selten, in ihrer Schwere aber nicht zu unterschätzen. Das Postembolisationssyndrom scheint beim Gebrauch abbaubarer Stärkepartikel im Vergleich zu Embolisaten mit lang anhaltender oder permanenter Okklusion seltener aufzutreten. Daher könnten unter palliativen Gesichtspunkten abbaubare Stärkepartikel von Vorteil sein. Sollten in Zukunft weitere Studien zur TACE von Lebermetastasen stattfinden, muss unter palliativen Gesichtspunkten mehr Augenmerk auf die Lebensqualität des Patienten gerichtet werden.

Abstract

Since two decades transarterial chemoembolization (TACE) of liver metastases has been investigated in numerous studies. However, no standardized therapeutic procedure exists so far.

The present study retrospectively investigated survival, response and side effects after TACE of liver metastases in 21 patients with colorectal cancer and results are compared with previous literature. A total of 68 TACE procedures were performed. A suspension of degradable starch microspheres (DSM, Spherex®) and Mitomycin C was applied selectively into hepatic arteries via a transfemoral approach. DSM effect a temporary arterial occlusion. Follow-up studies were performed by contrast enhanced spiral computed tomography (CT).

The median survival was 13.8 months. Therapeutic response (according to WHO) was observed only in three patients. The progression free interval was 5.8 months. Patients developed a postembolization-syndrome (abdominal pain, fever, nausea) and increased transaminases in 27–43% of all interventions. A gastric ulcer occurred after four, cholecystitis after two TACE.

As already shown in most previous studies, regardless of the used agents, also this investigation underlines the moderate therapeutic effect of TACE on colorectal liver metastases. So far, no significant survival benefit has been shown in the literature and the response rates are rather limited. In general, complications of TACE seem to be rare, but should not to be underestimated. Compared to TACE with long or permanent arterial occlusion, postembolization syndrome seems to be less pronounced using DSM. As TACE is rather a palliative therapeutic approach, DSM therefore might be more suited. Further studies on TACE of liver metastases should focus on to the patients’ quality of life.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

Abb. 1
Abb. 2a, b

Literatur

  1. Ackerman NB, Lien WM, Kondi ES, Silverman NA (1969) The blood supply of experimental liver metastases. I. The distribution of hepatic artery and portal vein blood to „small“ and „large“ tumors. Surgery 66:1067

    CAS  PubMed  Google Scholar 

  2. Ackerman NB (1972) Experimental studies on the circulatory dynamics of intrahepatic tumor blood supply. Cancer 29:435–439

    CAS  PubMed  Google Scholar 

  3. Amin Z, Bown SG, Lees WR (1993) Local treatment of colorectal liver metastases: a comparison of interstitial laser photocoagulation (ILP) and percutaneous alcohol injection (PAI). Clin Radiol 48:166–171

    CAS  PubMed  Google Scholar 

  4. Aronsen KF, Hellekant C, Holmberg J, Rothmann U, Teder H (1979) Controlled blocking of hepatic artery flow with enzymatic degradable microspheres combined with oncolytic drugs. Eur Surg Resp 11:99–106

    CAS  Google Scholar 

  5. Bengmark S, Jeppson B, Lunderquist A, Tranberg KG, Persson B (1988) Tumor calcification following repeated hepatic dearteralization in patients: a preliminary communication. Br J Surg 75:525–526

    CAS  PubMed  Google Scholar 

  6. Berger DH, Carrasco CH, Hohn DC, Curley SA (1995) Hepatic artery chemoembolization or embolization for primary and metastatic liver tumors: post-treatment management and complications. J Surg Oncol 60 116–121

    Google Scholar 

  7. Bläcker H, Hofmann WJ, Theurer D, Otto HF (2001) Pathologische Befunde bei Lebermetastasen. Radiologe 41:1–7

    Article  PubMed  Google Scholar 

  8. Bleiberg H, Pector C, Frühling J, Parmentier N, Gerard B, Gordon BH, Ings RMJ, Solere P, Lucas C (1992) Hepatic intra-arterial fotemustine combined with degradable starch microspheres: pharmacokinetics in a phase I-II trial. Reg Cancer Treat 4:237–243

    Google Scholar 

  9. Borner M, Castiglione M, Triller J, Soucek M, Blumgart L, Brunner K (1992) Considerable side effects of chemoembolization for colorectal carcinoma metastatic to the liver. Ann Oncol 3:113–115

    CAS  PubMed  Google Scholar 

  10. Breedis C, Young G (1954) The blood supply of neoplasms in the liver. Am J Pathol 30:969–977

    CAS  PubMed  Google Scholar 

  11. Civalleri D, Pector JC, Håkansson L, Arnaud JP, Duez N, Buyse M (1994) Treatment of patients with irresectable metastases from colorectal cancer by chemo-occlusion with degradable starch microspheres. Br J Surg 81:1338–1341

    CAS  PubMed  Google Scholar 

  12. Civalleri D, Scopinaro G, Balletto N, Claudiani F, DeCian F, Camerini G, DePaoli M, Bonalumi U (1989) Changes in vascularity of liver tumours after hepatic arterial embolization with degradable starch microspheres. Br J Surg 76:699–703

    CAS  PubMed  Google Scholar 

  13. Czejka M, Jäger W, Schüller J, Schernthaner G (1991) Pharmakokinetik und lokale Verfügbarkeit von Mitomycin. Einfluß von Vasokonstriktion und Chemoembolisation. Arzneimittelforschung 41:260–263

    CAS  PubMed  Google Scholar 

  14. De Dycker RP, Timmermann J (1991) Combined intraarterial hepatic infusion of degradable starch microspheres and cytostatics in the treatment of breast cancer liver metastases. Reg Cancer Treat 3:302–304

    Google Scholar 

  15. De Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, Boni C, Cortes-Funes H, Cervantes A, Freyer G, Papamichael D, Le Bail N, Louvet C, Hendler D, de Braud F, Wilson C, Morvan F, Bonetti A (2000) Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18:2938–2947

    PubMed  Google Scholar 

  16. Eibl-Eibesfeld B, Aichner I, Izbicki J, Kummermehr J, Waldner H, Wilker D (1989) Interaktion von Mitomycin C und Tumorischämie. Langenbecks Arch Chir [suppl]:1–4

  17. Ensminger WD, Gyves JW, Stetson P, Walker-Andrews S (1985) Phase I study of hepatic arterial degradable starch microspheres and mitomycin. Cancer Res 45:4464–4467

    CAS  PubMed  Google Scholar 

  18. Fiorentini G, Campanini A, Dazzi C, Davitti B, Graziani G, Priori T, Ricci Bitti R, Angelini L (1994) Chemoembolization in liver malignant involvement. Minerva Chir 49:281–285

    CAS  PubMed  Google Scholar 

  19. Fujimoto S, Koike S, Takahashi M, Mutou T, Kure M, Kobayashi K, Okkubo H (1993) Intra-arterial infusion chemotherapy with degradable starch microspheres and mitomycin C for unresectable hepatic metastasis from gastrointestinal cancer. Reg Cancer Treat 1:7–11

    Google Scholar 

  20. Gennari L, Doci R, Veronesi U (1982) Proposal for a clinical classification of liver metastases. Tumori 68:443–449

    CAS  PubMed  Google Scholar 

  21. Giacchetti S, Perpoint B, Zidani R, Le Bail N, Faggiuolo R, Focan C, Chollet P, Llory JF, Letourneau Y, Coudert B, Bertheaut-Cvitkovic F, Larregain-Fournier D, Le Rol A, Walter S, Adam R, Misset JL, Levi F (2000) Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 18:136–147

    CAS  PubMed  Google Scholar 

  22. Gross-Fengels W, Friedmann G, Kuhn M, Huber R, Dommasck J, Neufang KFR (1991) Techniken, Ergebnisse und Risiken der Chemoembolisation von malignen Lebertumoren. Akt Radiol 1:97–104

    CAS  Google Scholar 

  23. Haage P, Tacke J (2001) MR-gesteuerte perkutane Kryotherapie von Lebermetastasen. Radiologe 41:77–83

    Article  CAS  PubMed  Google Scholar 

  24. Håkansson L, Håkansson A, Morales O, Thorelius L, Warfving T (1997) Spherex (degradable starch microspheres) chemo-occlusion-enhancement of tumor drug concentration and therapeutic efficacy. an overview. Semin Oncol 24:100–109

    Google Scholar 

  25. Helmberger T, Holzknecht N, Schopf U, Kulinna C, Rau H, Stabler A, Reiser M(2001) Radiofrequenzablation von Lebermetastasen. Technik und erste Ergebnisse. Radiologe 41:69–76

    Article  CAS  PubMed  Google Scholar 

  26. Herfarth C, Hohenberger P (1989) Chirurgie der Metastasenleber. Langenbecks Arch Chir [suppl II]:263–268

  27. Herfarth KK, Debus J, Lohr F, Bahner ML, Wannenmacher M (2001) Stereotaktische Bestrahlung von Lebermetastasen. Radiologe 41:64–68

    Article  CAS  PubMed  Google Scholar 

  28. Hobday TJ, Goldberg RM (2002) Perspectives on the role of sequential or combination chemotherapy for first-line and salvage therapy in advanced colorectal cancer. Clin Colorectal Cancer 2:161–169

    CAS  PubMed  Google Scholar 

  29. Hunt TM, Flowerdew ADS, Birch SJ, Williams JD, Mullee MA, Taylor I (1990) Prospective randomized controlled trial of hepatic arterial embolization of infusion chemotherapy with 5-fluoruracil and degradable starch microspheres for colorectal liver metastases. Br J Surg 77:779–782

    CAS  PubMed  Google Scholar 

  30. Isenberg J, Fischbach R, Krüger I, Keller HW (1996) Treatment of liver metastases from colorectal cancer. Anticancer Res 16:1291–1296

    CAS  PubMed  Google Scholar 

  31. Kameyama M, Imaoka S, Fukuda I, Nakamori S, Sasaki Y, Fujita I, Hasegawa Y, Iwanaga T (1992) Delayed washout of intratumor blood flow is associated with good response to intraarterial chemoembolization for liver metastasis of colorectal cancer. Surgery 114:97–101

    Google Scholar 

  32. Kemen N, Niedzwiecki D, Shurgot B, Odermann P (1989) Prognostic variables in patients with hepatic metastases from colorectal cancer. Cancer 63:742–747

    PubMed  Google Scholar 

  33. Kettenbach J, Pokrajac B, Schamp S, Fellner C, Schmid R, Gustorff B, Berger J, Grgurin M, Peer K, Wolff U, Seitz W, Potter R, Lammer J (2001) MR-gestützte Brachytherapie nichtresektabler Lebermetastasen. Vorläufige technische und klinische Erfahrungen. Radiologe 41:56–63

    Article  CAS  PubMed  Google Scholar 

  34. Kobayashi H, Inoue H, Shimada J, Yano T, Maeda T, Oyama T, Shinohara S (1987) Intra-arterial injection of adriamycin/mitomycin C lipiodol suspension in liver metastases. Acta Radiol 28:275–280

    CAS  PubMed  Google Scholar 

  35. Köhne-Wömpner HJ, Schmoll HJ, Harstrick A, Rustum YM (1992) Chemotherapeutic strategies in metastatic colorectal cancer: an overview of current clinical trials. Semin Oncol 19 [suppl 3]:105–125

    Google Scholar 

  36. Lang EK, Brown CL (1993) Colorectal metastases to the liver: selective chemoembolization. Radiology 189:417–422

    CAS  PubMed  Google Scholar 

  37. Lehnert T, Golling M (2001) Indikation und Ergebnisse der Lebermetastasenresektion. Radiologe 41:40–48

    Article  CAS  PubMed  Google Scholar 

  38. Leichmann CG, Jacobson JR, Modiano M, Daniels JR, Zalupski MM, Dorishow JH, Fletcher WS, Macdonald JS (1999) Hepatic chemoembolization combined with systemic infusion of 5-fluorouracil and bolus leucoverin for patients with metastatic colorectal carcinoma: a Southwest Oncology Group Pilot Trial. Cancer 86:775–781

    Article  PubMed  Google Scholar 

  39. Lin G, Lunderquist A, Hägerstrand I, Boijsen E (1984) Postmortem examination of the blood supply and vascular pattern of small liver metastases in man. Surgery 96:517–526

    CAS  PubMed  Google Scholar 

  40. Llovet JM, Real MI, Montana X, Planas R, Coll S, Aponte J, Ayuso C, Sala M, Muchart J, Sola R, Rodes J, Bruix J (2002) Arterial embolization or chemoembolization versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomized controlled trial. Lancet 18:1734–1739

    Article  Google Scholar 

  41. Lorenz M, Hermann G, Kirkowa-Reinmann M, Herrhausen T, Henne T, Hottenrott C (1989) Temporary chemoembolization of colorectal liver metastases with degradable starch microspheres. Eur J Surg Oncol 15:453–462

    CAS  PubMed  Google Scholar 

  42. Martinelli DJ, Wadler S, Bakal CW, Cynamon J, Rozenblit A, Haynes H, Kaleya R, Wiernik PH (1994) Utility of embolization or chemoembolization as second-line-treatment in patients with advanced or recurrent colorectal carcinoma. Cancer 74:1706–1712

    CAS  PubMed  Google Scholar 

  43. Meakem TJ, Unger EC, Pond GD, Modiano MR, Alberts DR (1992) CT findings after hepatic chemoembolization. J Comput Assist Tomogr 16:916–920

    PubMed  Google Scholar 

  44. Miller AB, Hoogstraten B, Staquet M, Winkler A (1981) Reporting results of cancer treatment. Cancer 47:207–214

    CAS  PubMed  Google Scholar 

  45. Patt Y, Chuang V, Wallace S, Hersh E, Freireich E, Mavligit G (1981) The palliative role of hepatic arterial infusion and arterial occlusion in colorectal carcinoma metastatic to the liver. Lancet 1:349–350

    Article  CAS  PubMed  Google Scholar 

  46. Pentecost MJ (1993) Transcatheter treatment of liver metastases. Am J Roentgenol 160:1171–1175

    CAS  Google Scholar 

  47. Persson B, Jeppson B, Ekberg H (1990) Repeated dearteralization of hepatic tumors with an implantable occluder. Cancer 66:1139–1146

    CAS  PubMed  Google Scholar 

  48. Pickren JW, Tsukada Y, Lane WW (1982) Liver metastases: analysis of autopsy data. In: Gilbert HA, Weiss L (eds) Liver metastases. Hall Medical Publishers, Boston, pp 2–18

  49. Richter EI, Schultheis KH, Gebhardt C, Wurzer W (1992) Indikation zur Chemoembolisation maligner Tumoren. Radiologe 32:56–59

    CAS  PubMed  Google Scholar 

  50. Sanz-Altamira MP, Spence LD, Hubermann MS, Posner MR, Steele G, Perry LJ, Stuart KE (1997) Selective chemoembolization in the management of hepatic metastases in refractory colorectal carcinoma. Dis Colon Rectum 40:770–775

    CAS  PubMed  Google Scholar 

  51. Schultheis KH, Gebhardt C, Schwemmle K, Richter EI, Schmacher F (1990) Chemoembolisation kolorektaler Metastasen. Zent Bl Chir 115:933–947

    CAS  Google Scholar 

  52. Stangl R, Altendorf-Hofmann A, Charnley RM, Scheele J (1994) Factors influencing the natural history of colorectal liver metastases. Lancet 343:1405–1410

    Article  CAS  PubMed  Google Scholar 

  53. Starkhammer H, Håkansson L, Morales O, Svedberg J (1987) Intra-arterial mitomycin C treatment of unresectable liver tumours. Acta Oncol 26:295–300

    PubMed  Google Scholar 

  54. Strohmeyer T, Haugeberg G, Lierse W (1986) Vaskularisation von Lebermetastasen: eine korrosionsanatomische Studie. Acta Anat 126:172–176

    CAS  Google Scholar 

  55. Taguchi T, Ogawa N, Bunke B, Nilsson B, DSM Study Group (1992) The use of degradable starch microspheres (spherex) with intra-arterial chemotherapy for the treatment of primary and secondary liver tumors—results of a phase III clinical trial. Reg Cancer 4:161–165

    Google Scholar 

  56. Taguchi T (1994) Chemo-occlusion in the treatment of liver cancer. A new technique using degradable starch microspheres. Clin Pharmacokinet 26:176–191

    Google Scholar 

  57. Taniguchi H, Takahashi T, Yamaguchi T, Kiyoshi S (1989) Intraarterial infusion chemotherapy for metastatic liver tumors using multiple anti-cancer agents suspended in a lipid contrast medium. Cancer 64:2001–2006

    CAS  PubMed  Google Scholar 

  58. Tellez C, Benson AB, Lyster MT, Talamonti M, Shaw J, Braun MA, Nemcek AA, Vogelzang RL (1998) Phase II trial of chemoembolization for the treatment of metastatic colorectal carcinoma to the liver and review of the literature. Cancer 82:1250–1259

    Article  CAS  PubMed  Google Scholar 

  59. Vogl T, Mack M, Straub R, Zangos S, Woitaschek D, Eichler K, Engelmann K (2001) Thermische Ablation von Lebermetastasen. Aktueller Stand und Perspektiven. Radiologe 41:49–55

    Article  CAS  PubMed  Google Scholar 

  60. Vogl TJ, Zangos S, Balzer JO, Thalhammer A, Mack MG (2002) Transarterielle Chemoembolisation von Lebermetastasen: Indikationsstellung, Technik, Ergebnisse. Fortschr Röntgenstr 174:675–683

  61. Voigt W, Behrmann C, Schlueter A, Kegel T, Grothey A, Schmoll HJ (2002) A new chemoembolization protocol in refractory liver metastasis of colorectal cancer—feasability study. Onkologe 25:158–164

    Article  CAS  Google Scholar 

  62. Wagner JS, Adson MA, Heerden JA (1984) The natural history of hepatic metastases from colorectal cancer. Ann Surg 199:502–507

    CAS  PubMed  Google Scholar 

  63. Wollner IS, Walker-Andrews SC, Smith JE, Ensminger WD (1986) Phase II study of hepatic arterial degradable starch microspheres and mitomycin. Cancer Drug Deliv 4:279–284

    Google Scholar 

  64. Wood CB, Gillis CR, Blumgart LH (1976) A retrospective study of the natural history of patients with liver metastases from colorectal cancer. Clin Oncol 7:285–288

    Google Scholar 

  65. Yamashita Y, Takahashi M, Koga Y, Saito R, Nanakawa S, Hatanaka Y, Sato N, Nakashima K, Urata J, Yoshizumi K, Ito K, Sumi S (1990) Prognostic factors in liver metastases after transcatheter arterial embolization or arterial infusion. Acta Radiol 31:269–274

    CAS  PubMed  Google Scholar 

Download references

Interessenkonflikt:

Der korrespondierende Autor versichert, dass keine Verbindungen mit einer Firma, deren Produkt in dem Artikel genannt ist, oder einer Firma, die ein Konkurrenzprodukt vertreibt, bestehen.

Author information

Affiliations

  1. Institut für Klinische Radiologie, Universitätsklinikum Mannheim

    K. Wasser

  2. Klinik für Anästhesiologie und Operative Intensivmedizin, Universitätsklinikum Köln

    F. Giebel

  3. Institut für Klinische Radiologie, Universitätsklinkum Münster

    R. Fischbach

  4. Medizinische Klinik I, Universitätsklinikum Köln

    H. Tesch

  5. Onkologische Gemeinschaftspraxis Frankfurt

    H. Tesch

  6. Klinik für Diagnostische und interventionelle Radiologie, Henriettenstiftung Hannover

    P. Landwehr

  7. Institut für Klinische Radiologie, Universitätsklinikum Mannheim, Theodor-Kutzer-Ufer 1–3, 68167, Mannheim

    K. Wasser

Authors
  1. K. Wasser
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. F. Giebel
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. R. Fischbach
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. H. Tesch
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. P. Landwehr
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to K. Wasser.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Wasser, K., Giebel, F., Fischbach, R. et al. Transarterielle Chemoembolisation von Lebermetastasen kolorektaler Karzinome mit abbaubaren Stärkepartikeln (Spherex®). Radiologe 45, 633–643 (2005). https://doi.org/10.1007/s00117-004-1061-5

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00117-004-1061-5

Schlüsselwörter

  • Lebermetastasen
  • Chemoembolisation
  • Abbaubare Stärkepartikel

Keywords

  • Liver metastases
  • Chemoembolization
  • Degradable starch microspheres